ArticleFrontiers in psychiatry2025
Dependence on zopiclone: a case report.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zopiclone-associated hallucinations: a case report and database pharmacovigilance study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zopiclone, a cyclopyrrolone derivative, is commonly employed for the short-term treatment of different types of insomnia. In comparison to benzodiazepines, Zopiclone appears to have a lower risk of abuse potential and withdrawal symptoms. Nevertheless, as the use of Zopiclone has increased, reports of abuse and dependence have begun to surface in the literature. Case presentation: This case report describes a 43-year-old male patient who has been taking zopiclone for 12 years, with a maximum daily dose of 112.5 mg. Two days after discontinuing the medication, the patient experienced withdrawal symptoms such as palpitations, sweating, irritability, hallucinations, and impulsive behavior, which resulted in his admission to a psychiatric hospital. After 17 days of treatment with diazepam, quetiapine fumarate, magnesium valproate, and trazodone hydrochloride, the patient's withdrawal symptoms alleviated, sleep quality improved, and medication cravings decreased. Conclusion: Similar to benzodiazepines, Zopiclone may also result in abuse and dependency issues. Therefore, when prescribing Zopiclone, physicians must be fully aware of it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.